

Type 2 diabetes in adults: management (medicines update) Guideline update – committee meeting 5

Date: Monday, 1st March 2021

Location: Virtual committee meeting by Zoom

Minutes: Final

Committee members present:					
Chizo Agwu (CA)	Chair	Present for notes 1 – 5			
Sarah Ali	Consultant Diabetologist	Present for notes 1 – 5			
Chirag Bakhai	GP	Present for notes 1 – 5			
Neel Basudev	GP	Present for notes 1 – 5			
Augustin Brooks	Consultant Diabetologist	Present for notes 3 – 5			
Anne Dornhorst	Consultant Diabetologist	Present for notes 1 – 5			
Dorothy Frizelle	Mental health professional	Present for notes 1 – 5			
Hugh Gallagher	Renal Physician	Present for notes 1 – 5			
Sallianne Kavanagh	Pharmacist	Present for notes 1 – 5			
Sharon McCarthy	Diabetes Nurse	Present for notes 1 – 5			
Nicola Milne	Diabetes Nurse	Present for notes 1 – 5			
Soon Song	Consultant Diabetologist	Present for notes 1 – 5			
Annette Swinkels	Lay member	Present for notes 1 – 5			
Gosia Wamil	Cardiologist	Present for notes 1 – 5			

NICE team in attendance:					
Lucy Beggs (LB)	Technical Analyst (Health Economics)	Present for notes 1 – 5			
Becky Chadwick	Project Manager	Present for notes 1 – 5			
Jacqueline Durkin	Administrator	Present for note 1 only			
Gareth Franklin (GF)	Medicines Adviser	Present for notes 1 – 5			
Marie Harrisingh (MS)	Senior Technical Analyst	Present for notes 1 – 5			
Kathryn Hopkins	Technical Adviser	Present for notes 1-2, 4-5			
Johanna Hulme (JH)	Associate Director – Medicines Evidence and Advice	Present for notes 1 – 5			
James Jagroo	NICE Observer	Present for notes 1 – 5			
Thomas Jones (TJ)	Technical Analyst (Health Economics)	Present for notes 1 – 5			
Gregory Moran	NICE Observer	Present for notes 1 – 5			

Apologies:	
Rupert Franklin	NICE Guideline Commissioning Manager
Natasha Jacques	Pharmacist
Sue Spiers	NICE Associate Director
Corrinne Wykes	Lay member

1. Welcome, declarations of interest and minutes review

The Chair welcomed the Committee members and attendees to the 5th meeting on Type 2 diabetes in adults (medicines update) and introduced herself as the new Chair for this guideline, taking over from the previous Chair, Ibrahim Abubakar.

The Chair informed the Committee that apologies had been received, noted above.

The Chair asked everyone to verbally declare any interests that have arisen since the last

meeting, these are noted below. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Hugh Gallagher	Committee member, Renal Physician	Honorary Secretary of British Renal Society	Direct, non- financial professional and personal	Declare and participate
Nicola Milne	Committee member, Nurse	Attendance as part of an Advisory Board at meeting held by device company Nevro to discuss: Senza Spinal Cord Stimulation system for the treatment of chronic pain to include painful diabetic neuropathy.	Direct, financial	Declare and participate
Nicola Milne	Committee member, Nurse	Attendance at a non- promotional GP Practice Meeting: Looking beyond HbA1c Honorarium Boehringer Ingelheim	Direct, financial	Declare and participate

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

2. Summary of planned approach and scope of interim work

The Chair introduced Senior Technical Analyst Marie Harrisingh (MH), who provided a summary of the planned approach for this interim guideline update, and an outline of the timeline for the work.

The Chair thanked Marie for her presentation and the committee for their comments.

3. Health economics

The Chair introduced Technical Analysts (health economics), Thomas Jones (TJ) and Lucy Beggs (LB), who presented on the health economics for the guideline and asked the committee for input on clinical assumptions used in the HE model, and sources of evidence for costs and utility values.

The Chair thanked Thomas and Lucy for their presentation and the Committee for their feedback.

4. Integrating NICE content

The Chair introduced Medicines Adviser, Gareth Franklin and Associate Director, Medicines Evidence and Advice, Johanna Hulme, who presented to the Committee on the work being undertaken within the NICE Medicines team to bring recommendations from different NICE outputs together to help support decision-making. GF and JH invited the Committee to consider how NICE guidance for this topic could be integrated to address some of the issues with the current NG28 guideline recommendations.

The Chair thanked Gareth and Johanna for their presentation and the committee for their feedback.

5. AOB

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next meeting and brought the meeting to a close.

Date of next meeting: Wednesday, 7th April 2021 (9:15 to 13:00)

Location of next meeting: Virtual committee meeting by Zoom